CEACAM5 Drugs Market By Drug Type (Antibody Drug Conjugates, Monoclonal Antibodies, Bispecific Antibodies, Other Targeted Therapies); By Drug Development Stage (Clinical Stage Drugs, Preclinical Drugs); By Cancer Indication (Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Non Small Cell Lung Cancer, Other Solid Tumors); By Route of Administration (Intravenous Administration, Other Routes); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Research and Institutional Channels); By End User (Hospitals, Cancer Treatment Centers, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the CEACAM5 Drugs Market Size and What Is Shaping Its Clinical Landscape?

The Global CEACAM5 Drugs Market was valued at USD 125 million in 2025 and is projected to reach USD 988 million by 2032, expanding at a CAGR of 32.5% during 2026–2032, according to Strategic Market Research.

 

CEACAM5 Drugs market is an emerging precision oncology primarily designed as ADCs and monoclonal antibodies that selectively focused on therapies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), a tumor-associated antigen highly expressed across multiple epithelial cancers. The target is particularly relevant in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and other solid tumors.

 

The CEACAM5-targeted therapy landscape is primarily driven by antibody-drug conjugate (ADC) technology, where CEACAM5-specific antibodies are engineered to deliver highly potent anticancer payloads, including topoisomerase-1 inhibitors, directly to tumor cells. Merck KGaA’s Precemtabart tocentecan (Precem-TcT/M9140) is among the most advanced programs, utilizing an exatecan payload to target CEACAM5-positive metastatic colorectal and pancreatic cancers. Other emerging approaches include Pfizer Oncology’s SGN-CEACAM5C (PF-08046050), an investigational ADC for advanced solid tumors; LaNova Medicines’ LM-24C5, a next-generation CEACAM5 ADC; and EBC-129, a CEACAM5/CEACAM6 bispecific ADC designed to enhance tumor selectivity. Additional early-stage bispecific platforms are exploring multi-target strategies to improve efficacy against heterogeneous solid tumors.

 

In colorectal cancer, CEACAM5 is expressed in approximately 90% of tumors, representing a major target population with more than 1.9 million new global cases annually and around 150,000 new U.S. cases. In NSCLC, high CEACAM5 expression is observed in approximately 20–25% of non-squamous tumors, creating a potential target population of hundreds of thousands of patients globally.

 

Overall, the CEACAM5 drugs market represents a high-growth precision oncology opportunity, combining a validated tumor target, large solid-tumor patient populations, and rapidly advancing ADC technologies. Continued clinical success could establish CEACAM5-targeted therapies as important treatment options for patients with advanced colorectal, lung, pancreatic, and gastrointestinal cancers.

 

Leading and Fastest-Growing Segments in the CEACAM5 Drugs Market

By Drug Type

Leading Segment: Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates accounted for approximately 45% of the CEACAM5 Drugs Market, representing USD 56 million in 2025, and are projected to expand at a CAGR of 35.0% during 2026–2032. ADCs lead the segment because most active CEACAM5 therapeutic development has shifted toward targeted payload delivery, where CEACAM5 serves as a tumor-recognition mechanism for transporting potent cytotoxic agents into cancer cells. Leading programs such as Merck KGaA’s Precem-TcT/M9140 and Pfizer/Seagen’s PF-08046050 demonstrate the commercial focus on improving payload potency, linker stability, and tumor selectivity.

Fastest-Growing Segment: Antibody-Drug Conjugates (ADCs)

ADCs are also the fastest-growing drug type due to the advancement of multiple CEACAM5-directed clinical programs, including Phase III validation of Precem-TcT and early-stage development of next-generation ADC platforms using differentiated payloads such as TOP1 inhibitors and RAS pathway inhibitors.

 

By Drug Development Stage

Leading Segment: Clinical-Stage Drugs

Clinical-stage drugs accounted for approximately 72% of the CEACAM5 Drugs Market, representing USD 90 million in 2025, and are expected to expand at a CAGR of 34.2% during 2026–2032. This segment dominates because CEACAM5 development has moved beyond early target validation, with multiple programs now undergoing human testing. The segment is strengthened by Precem-TcT entering Phase III development and several Phase I/II candidates evaluating broader solid-tumor applications.

Fastest-Growing Segment: Clinical-Stage Drugs

Clinical-stage assets are expected to record the fastest growth because successful transition from early trials into pivotal studies could rapidly increase the commercial value of CEACAM5-targeted therapies.

 

By Cancer Indication

Leading Segment: Colorectal Cancer

Colorectal cancer accounted for approximately 42% of the CEACAM5 Drugs Market, representing USD 53 million in 2025, and is projected to expand at a CAGR of 31.8% during 2026–2032. It leads because CEACAM5 is highly expressed across colorectal tumors and represents the first indication where a CEACAM5-directed therapeutic has entered Phase III development. Merck KGaA’s PROCEADE-CRC-03 trial is evaluating Precem-TcT in previously treated metastatic colorectal cancer, making this indication the primary commercial validation pathway for the entire drug class.

Fastest-Growing Segment: Non-Small Cell Lung Cancer (NSCLC)

NSCLC is projected to be the fastest-growing indication, expanding at a CAGR of 35.2%, supported by continued investigation of CEACAM5-high patient populations and improved ADC designs. However, commercialization depends on overcoming previous clinical setbacks, including Sanofi’s discontinued tusamitamab ravtansine program after failure to meet its Phase III endpoint.

 

By Route of Administration

Leading Segment: Intravenous Administration

Intravenous administration accounted for approximately 95% of the CEACAM5 Drugs Market, representing USD 119 million in 2025, and is projected to expand at a CAGR of 32.8% during 2026–2032. It dominates because current CEACAM5 therapies are primarily biologics and ADCs requiring controlled infusion-based delivery in oncology settings.

Fastest-Growing Segment: Intravenous Administration

The segment remains the fastest-growing because all major clinical-stage CEACAM5 ADC programs, including Precem-TcT, PF-08046050, and BG-C477, rely on intravenous delivery.

 

By Distribution Channel

Leading Segment: Hospital Pharmacies

Hospital pharmacies accounted for approximately 55% of the CEACAM5 Drugs Market, representing USD 69 million in 2025, and are projected to expand at a CAGR of 31.5% during 2026–2032. They lead because CEACAM5 therapies are expected to be administered primarily through oncology centers requiring infusion infrastructure, biomarker assessment, and adverse-event monitoring.

Fastest-Growing Segment: Specialty Pharmacies

Specialty pharmacies are expected to grow fastest at a CAGR of 34.0%, supported by the future commercialization of advanced oncology biologics requiring specialized distribution, patient coordination, and reimbursement support.

 

By End User

Leading Segment: Hospitals

Hospitals accounted for approximately 48% of the CEACAM5 Drugs Market, representing USD 60 million in 2025, and are projected to expand at a CAGR of 31.8% during 2026–2032. Hospitals remain the primary end users because CEACAM5 therapies require oncology specialists, infusion facilities, pathology coordination, and monitoring of treatment-related toxicities.

Fastest-Growing Segment: Cancer Treatment Centers

Cancer treatment centers are expected to grow fastest at a CAGR of 33.5%, driven by their role in biomarker-guided oncology treatment, clinical-trial participation, and adoption of advanced ADC therapies.

 

By Geography

Leading Region: North America

North America accounted for approximately 46% of the CEACAM5 Drugs Market, representing USD 58 million in 2025, and is projected to expand at a CAGR of 30.8% during 2026–2032. The region leads due to strong oncology infrastructure, high clinical-trial activity, advanced biomarker testing capabilities, and participation of major pharmaceutical companies developing CEACAM5 therapies. The United States remains central because of its large colorectal cancer population, with NCI SEER estimating 158,850 new colorectal cancer cases in 2026.

Fastest-Growing Region: Asia Pacific

Asia Pacific is expected to record the fastest growth at a CAGR of 37.0%, supported by expanding participation in multinational clinical trials, growing oncology infrastructure, and increasing involvement of companies such as BeOne Medicines and Pfizer in regional CEACAM5 development programs.

 

Drug Type Innovation Redefining the CEACAM5 Drugs Market

Antibody-drug conjugates (ADCs) represented the largest technology segment in the CEACAM5 Drugs Market, accounting for approximately 45% of the market share and reaching USD 56 million in 2025. The segment is projected to expand at a CAGR of 35.0% during 2026–2032, driven by the growing demand for precision oncology approaches. ADCs function as targeted “smart bomb” therapies by specifically binding to the CEACAM5 protein expressed on cancer cells and delivering potent chemotherapy payloads directly into tumors. This targeted mechanism enables selective cancer-cell killing while potentially reducing systemic toxicity compared with conventional chemotherapy, making ADCs a key area of innovation in CEACAM5-directed cancer treatment.

 

CEACAM5 Drugs Market: From Early Discovery to Clinical Validation

Clinical-stage drugs accounted for approximately 72% of the market, representing USD 90 million in 2025, and are expected to expand at a CAGR of 34.2%. The segment has become increasingly substantial as Precem-TcT has advanced into Phase III and several next-generation programs have entered multinational early clinical testing. BMS-986490 is recruiting in a Phase I/IIa study across CEACAM5-expressing colorectal, gastric, and NSCLC populations, while BeOne Medicines is evaluating BG-C477 alone and with tislelizumab or chemotherapy in a Phase Ia/b program.

 

Cancer Indication Segmentation and Emerging Therapeutic Opportunities Across CEACAM5-Expressing Solid Tumors

Colorectal cancer (CRC) represents the largest application segment in the CEACAM5 Drugs Market, accounting for approximately 42% of the market share and reaching USD 53 million in 2025, with the segment projected to expand at a CAGR of 31.8%. CRC frequently exhibits overexpression of the CEACAM5 cell surface protein, making it a key biomarker and therapeutic target for next-generation CEACAM5-directed antibody-drug conjugates (ADCs). These targeted therapies are designed to selectively recognize CEACAM5-positive tumor cells, deliver cytotoxic payloads directly to malignant tissue, and improve treatment precision while addressing unmet needs in advanced colorectal cancer management. The strong biological relevance of CEACAM5 expression and ongoing ADC innovation are expected to drive continued growth within this segment.

Non-small cell lung cancer represented approximately 14% of the market, equivalent to USD 18 million in 2025, and has the highest indication CAGR at 35.2%. The opportunity is more selective than in CRC. A real-world pathology study of 600 NSCLC samples found high CEACAM5 expression in 18%, while moderate expression was observed in 43%. The same study found only moderate interobserver reliability in CEACAM5 assessment, emphasizing the importance of reproducible biomarker testing when enrollment depends on expression thresholds.

 

Route of Administration Trends Reshaping Treatment Delivery and Market Expansion in the CEACAM5 Drugs Market

Intravenous administration accounted for approximately 95% of the market, representing USD 119 million in 2025, and is projected to expand at a CAGR of 32.8%. Its dominance reflects the infusion-based delivery of major ADC programs and the need for monitored oncology administration. Precem-TcT is being developed for intravenous use, while BG-C477 is also administered intravenously in its Phase I program.

 

Distribution Channels Supporting Access to CEACAM5-Targeted Therapies

Hospital pharmacies accounted for approximately 55% of the market, representing USD 69 million in 2025, with a CAGR of 31.5%. Hospital-based oncology remains the most natural handling environment for CEACAM5 biologics because intravenous treatment, toxicity monitoring, biomarker review, and management of heavily pretreated patients are commonly coordinated within the same specialist setting.

Specialty pharmacies represented approximately 30% of the market, equivalent to USD 38 million in 2025, and are projected to expand at a CAGR of 34.0%. Their role is expected to become more relevant as CEACAM5 therapies move closer to commercialization and require oncology-specific distribution, payer coordination, inventory management, and patient-support infrastructure.

 

Where CEACAM5 Therapies Are Delivered, Developed, and Advanced

Hospitals accounted for approximately 48% of the CEACAM5 Drugs Market, representing USD 60 million in 2025, and are projected to expand at a CAGR of 31.8%. Their leading position reflects oncology infusion infrastructure, access to pathology services, and capacity to manage treatment-related hematologic and gastrointestinal toxicities associated with potent ADC payloads.

Cancer treatment centers represented approximately 37% of the market, equivalent to USD 46 million in 2025, with a CAGR of 33.5%. Specialized oncology centers are particularly important for CEACAM5 because patient selection may require tissue-based expression testing and because early adoption will likely occur among centers familiar with advanced ADCs and later-line solid-tumor treatment.

 

Regional Growth Engines: Clinical Development and Oncology Infrastructure Across the CEACAM5 Drugs Market

North America accounted for approximately 46% of the CEACAM5 Drugs Market, valued at around USD 58 million in 2025, and is projected to expand at a CAGR of 30.8% during the forecast period. The region is currently in a pre-commercial, clinical-stage adoption phase, as no FDA-approved therapies specifically targeting the CEACAM5 biomarker are available yet. However, strong oncology research infrastructure, high investment in precision medicine, and ongoing clinical development of CEACAM5-targeted therapies are expected to drive future market growth. The presence of leading biotechnology and pharmaceutical companies, along with increasing adoption of biomarker-driven cancer treatment approaches, positions North America as a key region for the advancement and commercialization of CEACAM5-targeted therapeutics.

Asia-Pacific (APAC) region accounted for approximately 18% of the market, reaching USD 23 million in 2025, and is projected to register the highest regional CAGR of 37.0%. The region’s rapid growth is primarily driven by increasing clinical research activity, local innovation initiatives, regional collaborative trials, and strategic pipeline expansion rather than broad commercial adoption at the current stage. Growing investment in clinical development, improved healthcare infrastructure, and rising focus on emerging therapeutic opportunities are expected to strengthen APAC’s role as a key growth market in the coming years.

 

Competitive Strategies Driving the CEACAM5 Drugs Market

Competition in the CEACAM5 Drugs Market is primarily shaped by ADC design, payload selection, therapeutic window, biomarker strategy, indication expansion, and the ability to demonstrate meaningful clinical benefit in difficult-to-treat solid tumors. Merck KGaA currently leads the market with the only active Phase III CEACAM5 therapeutic program, while Pfizer/Seagen represents the strongest next-generation ADC competitor with a multinational Phase I program. Other companies are developing earlier-stage approaches or provide important clinical lessons from previous CEACAM5 programs.

Merck KGaA

Merck KGaA holds the leading position in the CEACAM5 Drugs Market through precemtabart tocentecan (Precem-TcT/M9140), the most advanced CEACAM5-targeted therapeutic currently in development. The antibody-drug conjugate uses a CEACAM5-directed antibody linked to exatecan, a topoisomerase-1 inhibitor designed to deliver cytotoxic activity directly into tumor cells. The company has advanced the program into the Phase III PROCEADE-CRC-03 trial for previously treated metastatic colorectal cancer, where Precem-TcT is being evaluated against trifluridine/tipiracil plus bevacizumab. Colorectal cancer represents the strongest commercial opportunity because CEACAM5 expression is reported in approximately 90% of colorectal tumors, while NCI SEER estimates 158,850 new colorectal cancer cases and 55,230 deaths in the United States in 2026. Beyond colorectal cancer, Merck is expanding development into CEACAM5-high pancreatic cancer and other solid tumors, creating opportunities for future label expansion if pivotal results confirm clinical benefit.

Pfizer / Seagen

Pfizer and Seagen represent the second leading competitive force through PF-08046050 (formerly SGN-CEACAM5C), an investigational CEACAM5-directed ADC designed around a novel topoisomerase-1 inhibitor linker-payload system. The program reflects the industry's shift toward improving ADC performance through payload potency, intracellular release, and tumor-selective delivery rather than relying only on target expression. PF-08046050 is being evaluated in a Phase I clinical study across colorectal, pancreatic, gastric/gastroesophageal, lung, and other advanced solid tumors, including combination strategies. The program benefits from Pfizer's global oncology infrastructure and Seagen's established ADC expertise, positioning it as the closest competitive platform to challenge Merck's Precem-TcT if early clinical results support broader development.

Other Competitive Companies

• BeOne Medicines: BeOne Medicines is developing BG-C477, a CEACAM5-directed ADC in a Phase Ia/b clinical study evaluating monotherapy and combinations with therapies such as tislelizumab and chemotherapy. The program represents an emerging ADC competitor focused on combination-based treatment strategies.

• Bristol Myers Squibb: Bristol Myers Squibb is advancing BMS-986490, a CEACAM5-targeted investigational ADC being studied in Phase I/IIa trials across CEACAM5-expressing colorectal, gastric, and non-small cell lung cancer populations. The program is positioned around evaluating safety, early efficacy, and potential combination approaches.

• Adlai Nortye: Adlai Nortye is developing AN4035, a differentiated CEACAM5 ADC that uses a pan-RAS(ON) inhibitor payload rather than a conventional cytotoxic agent. The program entered global Phase I development after FDA IND clearance and first-patient dosing in Australia, creating a new approach for targeted RAS pathway inhibition.

• Sanofi — Historical Development Benchmark: Sanofi previously developed tusamitamab ravtansine, a CEACAM5-directed ADC that reached Phase III in CEACAM5-high non-small cell lung cancer but was discontinued after the CARMEN-LC03 study failed to meet its progression-free-survival endpoint.

• Roche — Historical Development Benchmark: Roche evaluated cibisatamab, a CEACAM5-targeted T-cell bispecific antibody, in metastatic colorectal cancer; discontinuation of the program highlighted the challenges of immune-cell engagement approaches compared with the current ADC-focused pipeline.

 

CEACAM5 Drugs Market Report Coverage Table

Report Coverage	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 125 million
Revenue Forecast in 2032	USD 988 million
Overall Growth Rate	32.5% CAGR (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million
Segmentation	By Drug Type, By Drug Development Stage, By Cancer Indication, By Route of Administration, By Distribution Channel, By End User, and By Geography
By Drug Type	Antibody-Drug Conjugates, Monoclonal Antibodies, Bispecific Antibodies, and Other Targeted Therapies
By Drug Development Stage	Clinical-Stage Drugs and Preclinical Drugs
By Cancer Indication	Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
By Route of Administration	Intravenous Administration and Other Routes
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, and Research and Institutional Channels
By End User	Hospitals, Cancer Treatment Centers, and Research Institutions
By Region	North America, Europe, Asia Pacific, Latin America, and Middle East and Africa
Country Scope	United States, Canada, United Kingdom, Germany, France, Italy, Spain, China, Japan, India, Australia, South Korea, Brazil, Mexico, Saudi Arabia, United Arab Emirates, and South Africa
Market Drivers	Growing CEACAM5 biomarker validation, advancement of antibody-drug conjugates, expanding colorectal and lung cancer treatment populations, improved payload and linker technologies, biomarker-guided patient selection, and increasing oncology clinical-trial activity
Customization Option	Available upon request